# A Study in Myeloproliferative Disorders

> **NCT01134120** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 80 (estimated)

## Conditions studied

- Myeloproliferative Disorders
- Thrombocythemia, Essential
- Polycythemia Vera
- Primary Myelofibrosis

## Interventions

- **DRUG:** LY2784544

## Key facts

- **NCT ID:** NCT01134120
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2014-04
- **Final completion:** 2018-02-22
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134120, "A Study in Myeloproliferative Disorders". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01134120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*